Table 1.
Inter-assay agreement evaluated by Cohen’s κ coefficient in defining the presence of a PD-L1-positive TIC and NTIC in patients with hepatocellular carcinoma (n = 100)
| E1L3N | 22c3 | 28-8 | SP263 | SP142 | |
|---|---|---|---|---|---|
| PD-L1+ TIC | |||||
| E1L3N | – | 0.211 | 0.175 | 0.235 | 0.209 |
| 22c3 | 0.222 | – | 0.313 | 0.396 | 0.222 |
| 28-8 | 0.175 | 0.313 | – | 0.257 | 0.199 |
| SP263 | 0.235 | 0.263 | 0.257 | – | 0.267 |
| SP142 | 0.209 | 0.222 | 0.199 | 0.267 | – |
| PD-L1+ NTIC | |||||
| E1L3N | – | 0.038 | 0.061 | 0.036 | 0.030 |
| 22c3 | 0.038 | – | 0.169 | 0.505 | 0.086 |
| 28-8 | 0.061 | 0.169 | – | 0.111 | 0.004 |
| SP263 | 0.036 | 0.505 | 0. | – | 0.041 |
| SP142 | 0.030 | 0.086 | 0.004 | 0.41 | – |
TIC immune infiltrate in tumour, NTIC immune infiltrate in cirrhosis